Comparing SIGA Technologies (SIGA) and Mirati Therapeutics (MRTX)
SIGA Technologies (OTCMKTS: SIGA) and Mirati Therapeutics (NASDAQ:MRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.
Risk & Volatility
SIGA Technologies has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500.
This table compares SIGA Technologies and Mirati Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|SIGA Technologies||$14.99 million||25.53||-$39.69 million||($0.49)||-9.90|
|Mirati Therapeutics||N/A||N/A||-$83.11 million||($3.11)||-5.53|
SIGA Technologies has higher revenue and earnings than Mirati Therapeutics. SIGA Technologies is trading at a lower price-to-earnings ratio than Mirati Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares SIGA Technologies and Mirati Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
6.7% of SIGA Technologies shares are owned by institutional investors. Comparatively, 64.7% of Mirati Therapeutics shares are owned by institutional investors. 4.7% of SIGA Technologies shares are owned by insiders. Comparatively, 5.1% of Mirati Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of current ratings and price targets for SIGA Technologies and Mirati Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mirati Therapeutics has a consensus price target of $14.25, indicating a potential downside of 17.15%. Given Mirati Therapeutics’ higher possible upside, analysts clearly believe Mirati Therapeutics is more favorable than SIGA Technologies.
Mirati Therapeutics beats SIGA Technologies on 7 of the 12 factors compared between the two stocks.
SIGA Technologies Company Profile
SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.